Solid Biosciences has spent a decade trying to deliver a safer, more muscle-selective gene therapy for Duchenne muscular dystrophy, and the first half of this year is the first time that story has a late-stage clock attached to it. The company dosed the first participant in IMPACT DUCHENNE, a placebo-controlled registrational study of its lead construct, and has asked the Food and Drug Administration for a year-end meeting on whether the open-label INSPIRE package can support an accelerated-approval discussion. That is a different equity than the one that lived and died with the first-generation Duchenne vector. The market is no longer paying for a science experiment. It is paying for a regulatory conversation, and for whether a next-generation capsid can do what the prior construct could not.
Cash nearly doubled after an oversubscribed March private placement and ongoing at-the-market sales, and management now describes a runway into the middle of two thousand twenty-eight. That buffer is real, but it was purchased with a large pre-funded-warrant overlay and a doubled authorized share count. Research spending is concentrating in manufacturing and clinical costs for the Duchenne file, which is the right allocation if the agency meeting opens a faster path and the wrong one if the agency wants years of confirmatory function before any label. The follow-on programs in Friedreich ataxia and catecholaminergic polymorphic ventricular tachycardia remain early, so they do not yet carry the equity.
The debate is whether the INSPIRE biomarker package and a still-clean safety record in more than fifty dosed participants convert into a credible path that does not require waiting for a full IMPACT readout. Twelve-month functional data from the earliest INSPIRE cohorts, the tone of the year-end agency meeting, and whether confirmatory enrollment outside the United States stays on schedule are the three observations that resolve that debate. If those land poorly, the cash still funds the company, but the multiple attached to the pipeline does not.